• MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement contractpharma
    February 23, 2021
    MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
PharmaSources Customer Service